Antihypertensive effects of oxprenolol and propranolol

Barry J. Materson, Ulrich F. Michael, James R. Oster, Eliseo C. Perez-Stable, Alba Hernandez, Mary Smith

Research output: Contribution to journalArticle

7 Scopus citations


The antihypertensive effects of the beta blockers oxprenolol and propranolol were compared in a randomized double-blind study of patients with standing diastolic pressures (SDP) exceeding 99 mm Hg when receiving hydrochlorothiazide alone. After 3 wk of hydrochlorothiazide with placebo, the latter was replaced with oxprenolol (n = 12) or propranolol (n = 12), 20 mg three times daily. Beta blocker was increased subsequently to 40 and 80 mg three times daily if SDP exceeded 89 ruin Hg. Nine oxprenolol and 7 propranolol subjects were hospitalized for 24-hr monitoring. With oxprenolol, standing pressure declined from 135 ± 2 (SE)/104 ± I mm Hg to 128 ± 3190 ± 2. SDP declined to under 91 mm Hg in 7 of 12 subjects, and to from 91 to 95 in 3 subjects. With propranolol, findings were 138 ± 31106 ± 2 to 123 ± 3189 ± 3; in 7 of 12 to less than 91 mm Hg and from 91 to 95 in 4 subjects. Decrements in supine and SDP were slightly (4 mm Hg) greater for propranolol than for oxprenolol. Both drugs gave similar 24-hr blood pressure control. We conclude that oxprenolol and propranolol used to supplement hydrochlorothiazide provide comparable reductions in blood pressure and smooth control over a 24-hr period in most patients with hypertension.

Original languageEnglish (US)
Pages (from-to)142-151
Number of pages10
JournalClinical Pharmacology and Therapeutics
Issue number2
StatePublished - Aug 1976

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Antihypertensive effects of oxprenolol and propranolol'. Together they form a unique fingerprint.

  • Cite this

    Materson, B. J., Michael, U. F., Oster, J. R., Perez-Stable, E. C., Hernandez, A., & Smith, M. (1976). Antihypertensive effects of oxprenolol and propranolol. Clinical Pharmacology and Therapeutics, 20(2), 142-151.